Is There Still a GLP-1 Shortage? How to Check FDA's List Yourself

As of October 27, 2026, semaglutide injection and tirzepatide injection aren't on FDA's current drug shortage list. FDA declared those shortages resolved in February 2025 and December 2024. Liraglutide injection still is, with some Victoza and Saxenda pens listed as limited. Shortage status can change at any time, though, so here's how to check it yourself in about two minutes.

If you're fuzzy on what "shortage" means compared with "discontinued" or "recalled," start with our explainer on the difference. This post is the hands-on how-to.

Where do semaglutide, tirzepatide and liraglutide stand right now?

Here's what FDA's Drug Shortages database showed when we checked on October 27, 2026:

Active ingredient	FDA database status	Notes
Semaglutide injection (Ozempic, Wegovy)	Not on the current shortage list	Resolved February 21, 2025, per FDA's compounding-policy page
Tirzepatide injection (Mounjaro, Zepbound)	Not on the current shortage list	Resolved October 2, 2024, and reaffirmed December 19, 2024
Liraglutide injection (Victoza, Saxenda, generics)	Currently in Shortage (first posted July 18, 2023)	Victoza pens "limited" with a shipping delay. Saxenda "limited" and available until discontinuation in January 2027. Generic liraglutide pens from Hikma, Meitheal and Teva-distributed product listed as available.
Semaglutide tablet (original Rybelsus 3/7/14 mg)	Discontinuation (posted June 4, 2026)	FDA's listing says these will be replaced by Ozempic (semaglutide) tablets

FDA also wrote in an April 1, 2026 update that tirzepatide and semaglutide "currently" appear on neither the shortage list nor the 503B bulks list. More on why that matters below.

How to check FDA's Drug Shortages database, step by step

FDA's shortage list is updated daily, according to its FAQ. Here's how to use it:

1. Open the database. Go to accessdata.fda.gov/scripts/drugshortages. (The FDA "Drug Shortages" page on fda.gov links there too.)
2. Search by active ingredient, not brand. Use the box labeled "Search by Generic Name or Active Ingredient." Type semaglutide, tirzepatide or liraglutide. Entries are named like "Liraglutide Injection" or "Semaglutide Tablet," so typing "Zepbound" won't get you far.
3. Check which tab you're on. The page has four tabs: Current/Resolved Shortages, Discontinuations, Therapeutic Categories (GLP-1s sit under Endocrinology/Metabolism), and New and Updated.
4. Read the status label next to the name. You'll see one of three:
   • Currently in Shortage: national supply isn't meeting demand right now.
   • Resolved: FDA's Drug Shortages Staff has determined that supply from at least one manufacturer covers total market demand. Some presentations can still be short.
   • Discontinuation: a manufacturer has told FDA it's permanently stopping a product.
5. Click through to the detail page. This is where the useful information is. Each company's products are listed by strength and NDC, with an availability note (for example "Available" or "Limited"), a reason, an estimated recovery if known, and the date the company last verified the info. The page also lists company phone numbers.
6. Check "New and Updated" if you're watching a product closely, or sign up for FDA's shortage email alerts (linked at the top of the page).
7. Note the date you checked. Resolved shortages stay visible for six months, and discontinued products for a year, per FDA's FAQ. After that they drop off. A missing entry usually means "no current issue," not "never happened."

Tip: If an ingredient isn't in the list at all, it isn't currently in shortage or recently resolved. That's what you'll see for tirzepatide today.

Should I check a second list?

The American Society of Health-System Pharmacists (ASHP) publishes its own drug shortage list at ashp.org/drug-shortages. It's aimed at pharmacists and doesn't always match FDA's list. FDA's database is the official national status. If the two disagree, or neither explains why your pharmacy can't get your strength, the pharmacist is your best next source.

Why can't my pharmacy get it if the shortage is "over"?

Because FDA judges shortages nationally. Its FAQ notes that when one pharmacy is out, it's usually a temporary distribution problem, not a national shortage. Even when it declared the semaglutide shortage resolved, FDA warned that people might still see "intermittent and limited localized supply disruptions."

A good script for the pharmacy call:

• "Is the problem my specific strength, or the product in general?"
• "Is it on order, and when do you expect it?"
• "Can another location in your chain, or another pharmacy, fill it?"
• "If not, what should I ask my prescriber about?"

Write down the date, who you spoke to and what they said. If you keep notes in GLPily's journal, a dated entry like "CVS Main St: 2.5 mg back-ordered, recheck Friday" saves you calling three times to remember what you were told.

Why does shortage status matter for compounded GLP-1s?

This is the part that affects prices you see online. Under federal law, compounders' room to make copies of approved drugs depends partly on whether the drug is on FDA's shortage list:

• 503B outsourcing facilities can generally compound from a bulk ingredient only if it's on the 503B bulks list or the drug is on the shortage list. FDA says neither applies to semaglutide or tirzepatide right now. On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the bulks list. Comments were due June 29, 2026.
• 503A pharmacies shouldn't regularly or in "inordinate amounts" compound essentially copies of commercially available drugs. FDA has said it doesn't intend to take action against one that fills four or fewer prescriptions of such a product in a calendar month.
• The grace periods are over. After the shortages were resolved, FDA gave compounders wind-down windows. For tirzepatide, those ran to February 18, 2025 (503A) and March 19, 2025 (503B). For semaglutide, they ran to April 22, 2025 (503A) and May 22, 2025 (503B).

So when a website says "compounded because of the shortage," check the date on that claim. Our guide to compounded GLP-1 red flags covers the other questions to ask.

What to do if your dose isn't available

• Don't ration, split or stretch doses on your own, and don't switch products without your prescriber.
• Don't fill the gap from an unfamiliar online seller. Shortage worries are exactly when counterfeits look tempting.
• Know your label's missed-dose rules. They differ by medicine. See missed GLP-1 dose instructions, and ask your prescriber if a gap runs long, because restarting sometimes means a lower dose.
• Report a new shortage you think FDA is missing through FDA's public reporting portal (linked from the database page), or email drugshortages@fda.hhs.gov about an existing one.

Common questions

Is there still a semaglutide shortage in 2026?

Not on FDA's list. FDA declared the semaglutide injection shortage resolved on February 21, 2025, and it wasn't on the current list when we checked on October 27, 2026. Local stock of specific strengths can still vary.

Is tirzepatide (Mounjaro, Zepbound) in shortage?

No. FDA resolved the tirzepatide injection shortage on October 2, 2024, and reaffirmed that on December 19, 2024. It isn't on the current list.

Is liraglutide still in shortage?

Yes. As of October 27, 2026, FDA lists liraglutide injection as "Currently in Shortage," with some brand pens limited and several generic pens available.

How often does FDA update the shortage list?

FDA's FAQ says the list is updated daily. Each detail page also shows when each company last verified its information.